Effects of Long-term Prophylactic Use of Rifaximin-a on Intestinal Microbial Composition and Resistome in Patients with Liver Cirrhosis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022234

Enrollment

Unknown

Registered

2019-03-31

Start date

2019-03-04

Completion date

Unknown

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Interventions

LC:takel the Rifaximin-a

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. patients diagnosed with cirrhosis; 2. older than 18 years; 3. with recent six months, episodes of hepatic encephalopathy more than 1 times (Conn score=2), and relief of illness (Conn score, 0 or 1) at the recruitment; 4. need using rifaximin-a for hepatic encephalopathy prophylaxis; 5. sign the informed consent form.

Exclusion criteria

Exclusion criteria: those who are allergic to rifampin have a clear gastrointestinal disease those who can not take oral medication patients with advanced liver cirrhosis are not expected to complete the entire study cycle

Design outcomes

Primary

Measure	Time frame
diversity of the gut microbial;	—

Countries

China

Contacts

Public ContactXiao Yonghong

the First Affiliated Hospital, Zhejiang University

xiao-yonghong@163.com+86 15168338848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026